Regarding the selected cutoffs of PD‐L1 expression (Table S3), most studies were all‐comer trials (n = 18, 69.23%),11, 12, 26, 27, 28, 31, 32, 34, 37, 39, 49, 52, 53, 58, 60, 63, 64, 65 regardless of PD‐L1 status; the other trials were a tumor proportion score (TPS) ≥1 (n = 2),45, 46 a TPS ≥50 (n = 1),51 a combined positive score (CPS) ≥1 (n = 3),13, 42, 48 or a CPS ≥10 (n = 2).40, 56. The gene discussed is CD274; the disease is neoplasm.